Short-term nonhormonal and nonsteroid treatment in West syndrome

Giuseppe Capovilla, Francesco Beccaria, Allesandra Montagnini, Raffaella Cusmai, Emilio Franzoni, Filomena Moscano, Giangennero Coppola, Marco Carotenuto, Giuseppe Gobbi, Stefano Seri, Rima Nabbout, Federico Vigevano

Research output: Contribution to journalArticle

Abstract

Purpose: West syndrome (WS) is considered an age-dependent epileptic encephalopathy and also a particular type of electrical epileptic status. Short-term hormonal or steroid treatment of WS with good efficacy is reported in the literature. The aim of this retrospective multiinstitutional study was to evaluate the early discontinuation of nonhormonal and nonsteroid treatment for WS. Methods: Twenty-two WS cases in which treatment was discontinued after a maximum of 6 months, were collected. Inclusion criteria were the presence of typical EEG hypsarrhythmia (HY) and video-EEG recorded epileptic spasms. Exclusion criteria were the presence of partial seizures or other seizure types before spasm onset. The patients were treated with vigabatrin (VGB) in 19 cases and nitrazepam (NTZ) in three. The dose range was 70-130 mg/kg/day for VGB and 0.7-1.5 mg/kg/day for NTZ. The drug was discontinued if spasms stopped and HY disappeared after a mean treatment period of 5.1 months (range, 3-6 months). All patients underwent repeated and prolonged awake and sleep video-EEG, both before and after drug discontinuation. Results: Cryptogenic (15) and symptomatic (seven) WS patients were included. All the symptomatic cases had neonatal hypoxic-ischemic encephalopathy. The mean age at spasm onset was 5.5 months (range, 3-7 months; median, 6). The interval between spasm onset and drug administration ranged from 7 to 90 days (mean, 23 days; median, 20). The interval between drug administration and spasm disappearance ranged from 2 to 11 days (mean, 6 days; median, 6 days). The interval between drug administration and HY disappearance ranged from 3 to 30 days (mean, 9 days; median, 10 days). Drugs were stopped progressively over a 30- to 60-day period. Follow-up ranged from 13 to 50 months (mean, 26 months; median, 22 months). None of our cases showed spasm recurrence. Conclusions: Our data show that successful nonhormonal and nonsteroid treatment can be shortened to a few months without spasm recurrence in patients with cryptogenic or postanoxic WS.

Original languageEnglish
Pages (from-to)1085-1088
Number of pages4
JournalEpilepsia
Volume44
Issue number8
DOIs
Publication statusPublished - Aug 1 2003

Fingerprint

Infantile Spasms
Spasm
Nitrazepam
Pharmaceutical Preparations
Vigabatrin
Electroencephalography
Therapeutics
Seizures
Brain Hypoxia-Ischemia
Recurrence
Brain Diseases
Age of Onset
Sleep
Retrospective Studies
Steroids

Keywords

  • Epilepsy
  • Infantile spasms
  • Treatment
  • West syndrome

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Capovilla, G., Beccaria, F., Montagnini, A., Cusmai, R., Franzoni, E., Moscano, F., ... Vigevano, F. (2003). Short-term nonhormonal and nonsteroid treatment in West syndrome. Epilepsia, 44(8), 1085-1088. https://doi.org/10.1046/j.1528-1157.2003.55402.x

Short-term nonhormonal and nonsteroid treatment in West syndrome. / Capovilla, Giuseppe; Beccaria, Francesco; Montagnini, Allesandra; Cusmai, Raffaella; Franzoni, Emilio; Moscano, Filomena; Coppola, Giangennero; Carotenuto, Marco; Gobbi, Giuseppe; Seri, Stefano; Nabbout, Rima; Vigevano, Federico.

In: Epilepsia, Vol. 44, No. 8, 01.08.2003, p. 1085-1088.

Research output: Contribution to journalArticle

Capovilla, G, Beccaria, F, Montagnini, A, Cusmai, R, Franzoni, E, Moscano, F, Coppola, G, Carotenuto, M, Gobbi, G, Seri, S, Nabbout, R & Vigevano, F 2003, 'Short-term nonhormonal and nonsteroid treatment in West syndrome', Epilepsia, vol. 44, no. 8, pp. 1085-1088. https://doi.org/10.1046/j.1528-1157.2003.55402.x
Capovilla G, Beccaria F, Montagnini A, Cusmai R, Franzoni E, Moscano F et al. Short-term nonhormonal and nonsteroid treatment in West syndrome. Epilepsia. 2003 Aug 1;44(8):1085-1088. https://doi.org/10.1046/j.1528-1157.2003.55402.x
Capovilla, Giuseppe ; Beccaria, Francesco ; Montagnini, Allesandra ; Cusmai, Raffaella ; Franzoni, Emilio ; Moscano, Filomena ; Coppola, Giangennero ; Carotenuto, Marco ; Gobbi, Giuseppe ; Seri, Stefano ; Nabbout, Rima ; Vigevano, Federico. / Short-term nonhormonal and nonsteroid treatment in West syndrome. In: Epilepsia. 2003 ; Vol. 44, No. 8. pp. 1085-1088.
@article{e4e075908f87419cb3fff5a8d82d4a63,
title = "Short-term nonhormonal and nonsteroid treatment in West syndrome",
abstract = "Purpose: West syndrome (WS) is considered an age-dependent epileptic encephalopathy and also a particular type of electrical epileptic status. Short-term hormonal or steroid treatment of WS with good efficacy is reported in the literature. The aim of this retrospective multiinstitutional study was to evaluate the early discontinuation of nonhormonal and nonsteroid treatment for WS. Methods: Twenty-two WS cases in which treatment was discontinued after a maximum of 6 months, were collected. Inclusion criteria were the presence of typical EEG hypsarrhythmia (HY) and video-EEG recorded epileptic spasms. Exclusion criteria were the presence of partial seizures or other seizure types before spasm onset. The patients were treated with vigabatrin (VGB) in 19 cases and nitrazepam (NTZ) in three. The dose range was 70-130 mg/kg/day for VGB and 0.7-1.5 mg/kg/day for NTZ. The drug was discontinued if spasms stopped and HY disappeared after a mean treatment period of 5.1 months (range, 3-6 months). All patients underwent repeated and prolonged awake and sleep video-EEG, both before and after drug discontinuation. Results: Cryptogenic (15) and symptomatic (seven) WS patients were included. All the symptomatic cases had neonatal hypoxic-ischemic encephalopathy. The mean age at spasm onset was 5.5 months (range, 3-7 months; median, 6). The interval between spasm onset and drug administration ranged from 7 to 90 days (mean, 23 days; median, 20). The interval between drug administration and spasm disappearance ranged from 2 to 11 days (mean, 6 days; median, 6 days). The interval between drug administration and HY disappearance ranged from 3 to 30 days (mean, 9 days; median, 10 days). Drugs were stopped progressively over a 30- to 60-day period. Follow-up ranged from 13 to 50 months (mean, 26 months; median, 22 months). None of our cases showed spasm recurrence. Conclusions: Our data show that successful nonhormonal and nonsteroid treatment can be shortened to a few months without spasm recurrence in patients with cryptogenic or postanoxic WS.",
keywords = "Epilepsy, Infantile spasms, Treatment, West syndrome",
author = "Giuseppe Capovilla and Francesco Beccaria and Allesandra Montagnini and Raffaella Cusmai and Emilio Franzoni and Filomena Moscano and Giangennero Coppola and Marco Carotenuto and Giuseppe Gobbi and Stefano Seri and Rima Nabbout and Federico Vigevano",
year = "2003",
month = "8",
day = "1",
doi = "10.1046/j.1528-1157.2003.55402.x",
language = "English",
volume = "44",
pages = "1085--1088",
journal = "Epilepsia",
issn = "0013-9580",
publisher = "Blackwell Publishing Inc.",
number = "8",

}

TY - JOUR

T1 - Short-term nonhormonal and nonsteroid treatment in West syndrome

AU - Capovilla, Giuseppe

AU - Beccaria, Francesco

AU - Montagnini, Allesandra

AU - Cusmai, Raffaella

AU - Franzoni, Emilio

AU - Moscano, Filomena

AU - Coppola, Giangennero

AU - Carotenuto, Marco

AU - Gobbi, Giuseppe

AU - Seri, Stefano

AU - Nabbout, Rima

AU - Vigevano, Federico

PY - 2003/8/1

Y1 - 2003/8/1

N2 - Purpose: West syndrome (WS) is considered an age-dependent epileptic encephalopathy and also a particular type of electrical epileptic status. Short-term hormonal or steroid treatment of WS with good efficacy is reported in the literature. The aim of this retrospective multiinstitutional study was to evaluate the early discontinuation of nonhormonal and nonsteroid treatment for WS. Methods: Twenty-two WS cases in which treatment was discontinued after a maximum of 6 months, were collected. Inclusion criteria were the presence of typical EEG hypsarrhythmia (HY) and video-EEG recorded epileptic spasms. Exclusion criteria were the presence of partial seizures or other seizure types before spasm onset. The patients were treated with vigabatrin (VGB) in 19 cases and nitrazepam (NTZ) in three. The dose range was 70-130 mg/kg/day for VGB and 0.7-1.5 mg/kg/day for NTZ. The drug was discontinued if spasms stopped and HY disappeared after a mean treatment period of 5.1 months (range, 3-6 months). All patients underwent repeated and prolonged awake and sleep video-EEG, both before and after drug discontinuation. Results: Cryptogenic (15) and symptomatic (seven) WS patients were included. All the symptomatic cases had neonatal hypoxic-ischemic encephalopathy. The mean age at spasm onset was 5.5 months (range, 3-7 months; median, 6). The interval between spasm onset and drug administration ranged from 7 to 90 days (mean, 23 days; median, 20). The interval between drug administration and spasm disappearance ranged from 2 to 11 days (mean, 6 days; median, 6 days). The interval between drug administration and HY disappearance ranged from 3 to 30 days (mean, 9 days; median, 10 days). Drugs were stopped progressively over a 30- to 60-day period. Follow-up ranged from 13 to 50 months (mean, 26 months; median, 22 months). None of our cases showed spasm recurrence. Conclusions: Our data show that successful nonhormonal and nonsteroid treatment can be shortened to a few months without spasm recurrence in patients with cryptogenic or postanoxic WS.

AB - Purpose: West syndrome (WS) is considered an age-dependent epileptic encephalopathy and also a particular type of electrical epileptic status. Short-term hormonal or steroid treatment of WS with good efficacy is reported in the literature. The aim of this retrospective multiinstitutional study was to evaluate the early discontinuation of nonhormonal and nonsteroid treatment for WS. Methods: Twenty-two WS cases in which treatment was discontinued after a maximum of 6 months, were collected. Inclusion criteria were the presence of typical EEG hypsarrhythmia (HY) and video-EEG recorded epileptic spasms. Exclusion criteria were the presence of partial seizures or other seizure types before spasm onset. The patients were treated with vigabatrin (VGB) in 19 cases and nitrazepam (NTZ) in three. The dose range was 70-130 mg/kg/day for VGB and 0.7-1.5 mg/kg/day for NTZ. The drug was discontinued if spasms stopped and HY disappeared after a mean treatment period of 5.1 months (range, 3-6 months). All patients underwent repeated and prolonged awake and sleep video-EEG, both before and after drug discontinuation. Results: Cryptogenic (15) and symptomatic (seven) WS patients were included. All the symptomatic cases had neonatal hypoxic-ischemic encephalopathy. The mean age at spasm onset was 5.5 months (range, 3-7 months; median, 6). The interval between spasm onset and drug administration ranged from 7 to 90 days (mean, 23 days; median, 20). The interval between drug administration and spasm disappearance ranged from 2 to 11 days (mean, 6 days; median, 6 days). The interval between drug administration and HY disappearance ranged from 3 to 30 days (mean, 9 days; median, 10 days). Drugs were stopped progressively over a 30- to 60-day period. Follow-up ranged from 13 to 50 months (mean, 26 months; median, 22 months). None of our cases showed spasm recurrence. Conclusions: Our data show that successful nonhormonal and nonsteroid treatment can be shortened to a few months without spasm recurrence in patients with cryptogenic or postanoxic WS.

KW - Epilepsy

KW - Infantile spasms

KW - Treatment

KW - West syndrome

UR - http://www.scopus.com/inward/record.url?scp=0042572288&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042572288&partnerID=8YFLogxK

U2 - 10.1046/j.1528-1157.2003.55402.x

DO - 10.1046/j.1528-1157.2003.55402.x

M3 - Article

C2 - 12887441

AN - SCOPUS:0042572288

VL - 44

SP - 1085

EP - 1088

JO - Epilepsia

JF - Epilepsia

SN - 0013-9580

IS - 8

ER -